SCHEMBL11100

SCHEMBL11100

O=C(Cc1cccc(F)c1)c1cc(Br)ccc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.47
ALOX15 P16050 2/20 0.47
CES2 O00748 1/20 0.47
GALR3 O60755 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CASP1 P29466 1/20 0.47
CYP2C19 P33261 1/20 0.47
PIK3CA P42336 2/20 0.46
GSTA1 P08263 1/20 0.45
MAPT P10636 5/20 0.45
HTT P42858 4/20 0.45
NPC1 O15118 3/20 0.45
KDM4E B2RXH2 3/20 0.45
RAB9A P51151 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
MEN1 O00255 2/20 0.45
TSHR P16473 2/20 0.45
KMT2A Q03164 2/20 0.45
HSD17B10 Q99714 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30494456 1.00 HPGD (0.47) HPGDALOX15CES2GALR3CYP1A2
SCHEMBL150248 0.88 HTT (0.50) HPGDALOX15PIK3CAMAPTHTT
SCHEMBL29895835 0.88 HTT (0.50) HPGDALOX15PIK3CAMAPTHTT
SCHEMBL152533 0.87 ALOX15 (0.51) HPGDALOX15CES2GALR3CYP1A2
SCHEMBL29980690 0.84 DGAT1 (0.49) CYP1A2CYP2C9CYP2C19PIK3CAMAPT
SCHEMBL150523 0.84 LMNA (0.60) HPGDALOX15CES2GALR3CYP1A2
SCHEMBL149097 0.83 GSTA1 (0.56) HPGDALOX15CES2GALR3CYP1A2
SCHEMBL149865 0.82 HTT (0.61) HPGDALOX15PIK3CAMAPTHTT
SCHEMBL10560970 0.82 LMNA (0.54) HPGDALOX15PIK3CAMAPTHTT
SCHEMBL10561782 0.81 PIK3CA (0.68) HPGDALOX15PIK3CAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
WO-2023130334-A1 METHOD FOR PREPARING CHROMEN-4-ONE COMPOUND AND INTERMEDIATE THEREOF 同润生物医药(上海)有限公司 2023-07-13 WO disclosed
WO-2023130334-A1 METHOD FOR PREPARING CHROMEN-4-ONE COMPOUND AND INTERMEDIATE THEREOF 同润生物医药(上海)有限公司 2023-07-13 WO disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 EP disclosed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 EP disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 US disclosed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 US disclosed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 EP disclosed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 EP disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 HPGD 2895/4885ALOX15 4325/4885CES2 2414/4885
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HPGD 2910/4885ALOX15 3906/4885CES2 3351/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HPGD 2910/4885ALOX15 3906/4885CES2 3351/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HPGD 2910/4885ALOX15 3906/4885CES2 3351/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HPGD 2910/4885ALOX15 3906/4885CES2 3351/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HPGD 2910/4885ALOX15 3906/4885CES2 3351/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A HPGD 1641/4885ALOX15 2478/4885CES2 3409/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HPGD 2910/4885ALOX15 3906/4885CES2 3351/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HPGD 2910/4885ALOX15 3906/4885CES2 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.